Mesoblast Cell Therapy Products are Designated U.S. Origin and Not Subject to Tariffs

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reiterated that its allogeneic cell therapy products are manufactured from U.S ...
TipRanks on MSN

Mesoblast’s U.S. Origin Cell Therapies Exempt from Tariffs

Mesoblast Limited ( ($AU:MSB) ) has provided an announcement. Mesoblast Limited announced that its allogeneic cell therapy products, manufactured ...

Seres Therapeutics, Inc.: Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend ...

Following recent constructive FDA feedback, Seres anticipates finalizing SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem ...
Technology Networks

Stem Cell Advances Reshape Alzheimer’s Research and Treatment

This article explores how stem cell therapies and organoid models are advancing Alzheimer’s research. It highlights progress ...

Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway

Following recent constructive FDA feedback, Seres anticipates finalizing SER-155 Phase 2 study protocol for the prevention of bloodstream ...
Technology Networks

Gene Therapy for Deadly Blood Disorder Restores Function in Patients' Cells

UCLA researchers have made strides in developing a stem cell gene therapy for alpha thalassemia major, a severe, inherited ...

Loneliness can be deadly for cancer patients. This app helps foster connections

CancerBuddy connects users through shared diagnoses and experiences, offering community when hospital walls feel especially ...
British Journal of Ophthalmology

Assessment of tear and blood cytokines in chronic ocular graft-versus-host disease

Aims To assess cytokine levels in peripheral blood and tears of patients after allogeneic haematopoietic stem cell ...
PharmiWeb

JCR Pharmaceuticals and Alexion Achieve Milestone in Collaborative Neurodegenerative Disease Program

JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, has achieved a key research milestone in ...
PharmiWeb

No Difference in Transplant Outcomes Seen for Patients Unlikely to Find a Matched Unrelated Donor When a Donor Search Prognosis Strategy is Used

Published in the Journal of Clinical Oncology, results showed no difference in any outcomes, including overall survival, at two years post-evaluabilityFirst national, multi-center study to evaluate ...
Mirage News

UC Davis Gets $2.8M NIH Grant for AI Pathology Tool

UC Davis Health gastroenterology researchers have received a $2.8 million grant (R01EB037526) from the National Institute of ...